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 CURRENTOPINION Recent advances in cerebrospinal fluid biomarkers
for the detection of preclinical Alzheimer’s disease
Luka Kulica,b,c,d and Paul G. Unschuld a,b,c
Purpose of review
The concept of preclinical Alzheimer’s disease has emerged to describe the long ‘silent’ phase of the
disease when significant pathophysiological changes occur in the brain but clinical symptoms are not yet
manifest. In this review, a summary of the recent advances in cerebrospinal fluid (CSF) biomarker-based
diagnostics of preclinical Alzheimer’s disease will be presented.
Recent findings
The association between core CSF biomarkers of Alzheimer’s disease and between CSF and neuroimaging
markers has been a major focus of various recently published studies in cognitively healthy individuals.
Longitudinal results from several research groups suggest that CSF Ab42 is altered early in preclinical
Alzheimer’s disease, even preceding changes on amyloid PET imaging. In line with the proposed NIA-AA
criteria, elevated tau levels and/or Ab/tau interactions appear to be a prerequisite for neurodegeneration and
future cognitive decline. Novel candidate CSF markers, including markers of neuronal and synaptic injury as
well as neuroinflammation, may complement CSF-based diagnostics in preclinical Alzheimer’s disease.
Summary
Further longitudinal research is necessary to delineate the temporal changes of core and candidate CSF
biomarkers in preclinical Alzheimer’s disease and to investigate their association with established and
emerging neuroimaging markers as well as with comorbidities and other risk factors for age-related
cognitive decline.
Keywords
biomarker, cerebrospinal fluid, cognitive decline, neuroimaging, preclinical Alzheimer’s disease
INTRODUCTION
Alzheimer’s disease is the most frequent cause of
age-related cognitive and functional decline and a
growing socioeconomic challenge for healthcare
systems of the 21st century worldwide [1]. By the
time cognitive symptoms are traditionally diag-
nosed, significant neurodegenerative changes are
already detectable in the brain and opportunities
for causal disease-modifying therapeutic approaches
are limited. Alzheimer’s disease-related pathophy-
siological changes can be detected as early as 10–20
years before overt cognitive impairment [2]. The
detection of these changes as biomarkers by neuro-
imaging techniques and/or by biochemical assays in
the cerebrospinal fluid (CSF) has led to a conceptual
shift in the field of early Alzheimer’s disease diag-
nostics. The new diagnostic framework for preclin-
ical Alzheimer’s disease comprises biomarker-based
research criteria developed by the workgroups of the
National Institute on Aging – Alzheimer’s Associ-
ation (NIA-AA) [3] and those proposed by the Inter-
national Working Group (IWG-2) [4]. A special focus
of the NIA-AA criteria is laid on the early preclinical
disease stages and the assumption that Alzheimer’s
disease can be regarded as a continuum ranging from
normal cognition without evidence of Alzheimer’s
disease biomarker abnormalities to full-blown path-
ology including neuronal injury and cognitive
decline [3,5
&&
]. As such, theNIA-AAcriteria are closely
aInstitute for Regenerative Medicine, bClinic for Psychogeriatric
Medicine, cNeuroscience Center Zurich (ZNZ) and dZurich Center for
Integrative Human Physiology (ZIHP), University of Zurich, Zurich,
Switzerland
Correspondence to Dr Luka Kulic, Institute for Regenerative Medicine -
IREM, University of Zurich,Wagistrasse 12, 8952 Schlieren, Switzerland.
Tel: +41 44 634 8848; fax: +41 44 634 8874;
e-mail: luka.kulic@irem.uzh.ch
Curr Opin Neurol 2016, 29:749–755
DOI:10.1097/WCO.0000000000000399
This is an open-access article distributed under the terms of the Creative
Commons Attribution-Non Commercial-No Derivatives License 4.0
(CCBY-NC-ND), where it is permissible to download and share the work
provided it is properly cited. The work cannot be changed in any way or
used commercially without permission from the journal.
1350-7540 Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved. www.co-neurology.com
REVIEW
 Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.
centered on the amyloid cascade hypothesis [6] and
the model proposed by Jack et al. suggesting an
ordered fashion of temporal biomarker changes
during preclinical and clinical disease
progression [7,8]. Isolated amyloidosis (represented
by reducedCSFAb42and/orbypositive amyloidPET)
has been defined as the earliest stage of preclinical
Alzheimer’s disease (stage 1) according to current
NIA-AA criteria [3]. Consecutive stage 2 is character-
izedbyadditional evidenceofneuronal injuryand/or
neurodegeneration (as revealed by elevated CSF tau/
p-tau, Alzheimer’s disease-related hypometabolism
on [18F]FDG PET and/or atrophy on MRI) [3]. Lastly,
a preclinical Alzheimer’s disease stage 3 has been
defined to describe individuals with subtle cognitive
decline in addition to positive Ab and neuronal
injury/neurodegeneration biomarkers [3]. The NIA-
AA staging criteria of preclinical Alzheimer’s disease
are based on several hypothetical assumptions,
which have recently been supported or challenged
bydifferent groups, for example, the assumption that
Alzheimer’s disease biomarkers follow an invariable
sequenceof temporal changesor that certainCSF and
imagingmarkers may be treated as if they were inter-
changeable [9].
In this review, a summary of the recent advances
in CSF biomarker-based detection of preclinical
Alzheimer’s disease will be presented. A special focus
will be laid on the relationship between CSF
Alzheimer’s disease biomarkers and neuroimaging
markers and on the temporal sequence of biomarker
changes during preclinical disease progression.
RELATIONSHIP BETWEEN CORE
CEREBROSPINAL FLUID BIOMARKERS
AND IMAGING MARKERS OF
NEURODEGENERATION IN PRECLINICAL
ALZHEIMER’S DISEASE
The association between the core CSF Alzheimer’s
disease biomarkers Ab42, tau, and p-tau and imag-
ing measures of neuronal injury has recently been
addressed by several authors both in cross-sectional
and in longitudinal studies.
Vos et al. [10
&
] classified 212 cognitively healthy
individuals according to the NIA-AA criteria and
found a surprisingly low concordance (<60%)
between imaging (hippocampal volume) and CSF
(tau/p-tau) measures, thereby highlighting the need
for further refinement and investigation into the
relationship between CSF and imaging markers
of neurodegeneration.
In a cross-sectional study including 188 cogni-
tively healthy individuals, Wang et al. [11
&
] inves-
tigated the association between neurodegeneration
measured by structural MRI and the core CSF
biomarkers Ab42 and tau. The authors found that
CSF Ab42 and tau were linked to spatially distinct
patterns of atrophy. Although reduced Ab42 was
associated with isolated hippocampal atrophy, elev-
ated tau levels were related to thinning in several
Alzheimer’s disease-relevant cortical brain regions
[11
&
]. Notably, the CSF Ab42 status had no signifi-
cant influence on the association between tau and
cortical atrophy in this study, suggesting the exist-
ence of both Ab-independent and Ab-dependent
pathways of neurodegeneration in preclinical
Alzheimer’s disease [11
&
].
In another cross-sectional study with 145 cog-
nitively intact individuals Fortea et al. [12
&
] analyzed
the interaction between CSF Ab42 and p-tau across
the whole cortical mantle. In contrast to Wang et al.
the authors observed that taumodified the effects of
Ab on cortical thickness in various cortical regions
and vice versa. Interestingly, the presence of Ab
(measured by decreased CSF Ab42) in the absence
of p-tau was associated with cortical thickening, for
example explained by increased amyloid-related
inflammatory changes, while in the presence of
tau these effects were reversed towards neurodegen-
eration and cortical thinning in individuals who
were positive both for Ab and for p-tau [12
&
].
The usefulness of baseline CSF tau and p-tau in
predicting rates of whole-brain and regional medial
temporal lobe atrophy in preclinical Alzheimer’s
disease has recently also been addressed in a longi-
tudinal study with early Alzheimer’s disease patients
and cognitively healthy control individuals who
were followed up over a period of 2–3 years [13
&
].
Notably, cognitively intact individuals with CSF
levels of total tau and p-tau in the upper tercile
showed significantly increased atrophy rates when
compared to healthy controls with levels in the
lower two terciles [13
&
].
On the basis of hypothesis that synergistic inter-
actions between Ab and tau pathology drive
Alzheimer’s disease-related neurodegeneration and
neurometabolic dysfunction Pascoal et al. [14
&
]
KEY POINTS
 Longitudinal results suggest that CSF Ab42 is altered
early in preclinical Alzheimer’s disease.
 Elevated CSF tau levels and/or CSF Ab/tau
interactions appear to be a prerequisite for
neurodegeneration and future cognitive decline.
 Novel candidate CSF markers, including markers of
neuronal and synaptic injury as well as
neuroinflammation, may complement CSF-based
diagnostics in preclinical Alzheimer’s disease.
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assessed 120 cognitively healthy individuals who
had undergone CSF tap and [18F]florbetapir amyloid
PET at baseline in addition to an [18F]FDG PET for
glucose at baseline and at 24 months of follow-up.
Voxel-based analysis revealed a decline in the
[18F]FDG standardized uptake value ratio (SUVR)
in various limbic brain regions. Interestingly, this
[18F]FDG SUVR decline was significantly affected by
the interaction between [18F]florbetapir SUVR and
CSF p-tau, while the main effects of [18F]florbetapir
and CSF p-tau were not significant, suggesting
a synergism between Ab and p-tau in driving meta-
bolic decline in preclinical Alzheimer’s disease [14
&
].
The recent introduction of tau PET tracers has
provided a valuable tool to investigate the spatial
and temporal relationship between cerebral tau
accumulation and established CSF measures of Alz-
heimer’s disease pathology. In a first cross-sectional
study in preclinical Alzheimer’s disease, Gordon
et al. [15
&&
] found a significant association between
CSF Ab42, but not total tau and p-tau, and elevated
binding of the tau tracer [18F]AV-1451 in the medial
temporal lobes and adjacent cortices of cognitively
intact individuals. Interestingly, a positive corre-
lation between PET and CSF tau-related measures
was observed when a combined analysis of both
cognitively healthy and cognitively impaired indi-
viduals (CDR 0.5) was performed, which was
mainly driven by the cognitively impaired individ-
uals and associated with a more widespread uptake
of the tau tracer in neocortical brain regions [15
&&
].
CORE CEREBROSPINAL FLUID
BIOMARKER TRAJECTORIES AND
AMYLOID IMAGING IN PRECLINICAL
ALZHEIMER’S DISEASE
Sutphen et al. [16
&&
] characterized the within-person
trajectories of various Alzheimer’s disease CSF bio-
markers in a longitudinal cohort of 169 cognitively
intact middle-aged individuals who had undergone
serial lumbar punctures and longitudinal clinical
assessments as well as – in a subset of individuals –
amyloid PET imaging. In support of the NIA-AA
criteria suggesting an age-related transition between
stage 1 (characterized by amyloid pathology only)
and stage 2 (amyloidosis and presence of signs of
neuronal injury), the authors found CSF levels of
Ab42 decreasing over time as early as during
early middle age (45–54 years). These early changes
were associated with significant elevations in the
neuronal injury markers total tau and p-tau during
mid middle age (55–64 years) and late middle age
(65–74years) [16
&&
]. As amajoroutcome, decreases in
CSFAb42were found even before detectable amyloid
deposition on [11C]PiB PET imaging in mid middle
age [16
&&
]. Together with the observation that in
some individuals [11C]PiB binding was still below
the threshold of positivity while CSF Ab42 levels
were already low, these results imply that changes
in CSF Ab42 may precede [11C]PiB [16
&&
]. In support
of these findings are recent cross-sectional data
from a large familial Alzheimer’s disease kindred of
presymptomatic individuals carrying the Presenilin
1 E280A mutation in whom changes in CSF Ab42
were detectable 20 years before the kindred’s esti-
mated mild cognitive impairment (MCI) diagnosis
and 4 years prior to amyloid positivity on [18F]flor-
betapir PET imaging [17].
The association between baseline CSF Ab42 and
longitudinal Ab accumulation on amyloid PET has
further been assessed in two recent longitudinal
cohort studies. Palmqvist et al. [18
&
] investigated
whether abnormal Ab accumulation can be detected
by CSF analysis prior to amyloid PET in 437 non-
demented individuals that included both cogni-
tively intact individuals and patients with MCI.
The authors found that individuals with abnormal
CSF Ab42, but normal [18F]florbetapir PET at base-
line (‘CSFþ/PET’), showed a significantly acceler-
ated rate of cerebral Ab accumulation on follow-up
amyloid PET which resembled the rate in individ-
uals with both abnormal CSF and PET findings
(‘CSFþ/PETþ’). Interestingly, no ‘CSF/PETþ’ indi-
viduals were identified in this study, suggesting that
CSF changes can indeed be detected prior to PET
abnormalities [18
&
]. Together with the observation
that ‘CSFþ/PET’ individuals showed no memory
decline and similar changes in hippocampal volume
as ‘CSF/PET’ individuals over time, these results
strongly indicate that CSF Ab42 levels are altered
in the earliest (preclinical) stages of Alzheimer’s
disease [18
&
].
In another longitudinal study, Racine et al. [19]
collected baseline CSF from 104 cognitively intact
individuals (mean age 61.15 years) who were
enriched with Alzheimer’s disease risk factors (APOE
e4 genotype; positive family history of sporadic
Alzheimer’s disease). Linearmixed-effects regression
analysis revealed that at baseline CSF Ab42/Ab40
ratio and various other ratios of CSF proteins
to Ab42, including total and p-tau, predicted
longitudinal [11C]PiB uptake in Alzheimer’s
disease-vulnerable brain regions over 2 years [19].
In contrast to the authors’ initial hypothesis, no
significant associations between baseline CSF
ratios (including those with markers of neuronal
injury such as total tau in the numerator) and slopes
of episodic memory were detected suggesting that
Alzheimer’s disease-related preclinical cognitive
decline may be too subtle in this relatively young
cohort of cognitively healthy individuals [19].
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In a serial CSF sampling study including 35
cognitively healthy individuals who were followed
up longitudinally over a period of up to 3 years,
Mattsson et al. [20
&
] investigated whether baseline
CSF levels of Ab42 and p-tau predicted future amy-
loid positivity defined as declining CSF Ab42 levels
below an priori-defined threshold of 192ng/l.
Importantly, all participants included in this study
had normal CSF Ab42 levels at baseline. Although
10 out of 11 ‘decliners’ showed baseline CSF Ab42
levels in the lower tertile of the reference range
(<225ng/l), the majority of ‘nondecliners’ had
CSF Ab42 levels in the two upper tertiles [20
&
]. Base-
line p-tau levels also predicted future CSF Ab42
decline; baseline CSF Ab42 in the low normal range,
however, turned out to be the strongest predictor of
future amyloid positivity suggesting that in cogni-
tively normal individuals a less stringent (i.e.,
higher) cutoff level may be considered [20
&
].
The fact that both CSF Ab42 and p-tau predicted
future amyloidosis in this study might imply that
the two pathologies are coupled early in Alzheimer’s
disease pathogenesis. In line with this notion,
Gomar et al. [21
&
] observed in a subset of cognitively
normal individuals a strong temporal coincidence of
CSF trajectories of Ab42 and p-tau, which were
anticorrelated in individuals with declining CSF
Ab42 levels over time.
In a cross-sectional preclinical Alzheimer’s
disease study with 38 cognitively normal individ-
uals, Adamczuk et al. [22] assessed the diagnostic
accuracy of CSF Ab42 versus CSF Ab42/total-tau,
Ab42/Ab40 and Ab42/Ab38 in identifying amy-
loid-positivity on [18F]flutemetamol PET imaging.
Interestingly, when sensitivity and specificity were
combined, the ratios to Ab42 did not discriminate
significantly better between amyloid-positive and
amyloid-negative individuals than CSF Ab42 alone.
With a fixed specificity at 90 or 95%, however,
Ab42/total-tau showed the highest sensitivity,
suggesting that a CSF-based diagnosis of preclinical
Alzheimer’s disease should include both biomarkers
in cases when a high specificity is required (e.g., in
therapeutic clinical trials) [22].
CORE CEREBROSPINAL FLUID
BIOMARKERS AND PREDICTION OF
COGNITIVE DECLINE
An important concern raised in preclinical Alz-
heimer’s disease clinical trials lies in the challenge
to identify patients who are likely to show greatest
clinical progression if untreated. Soldan et al. [23
&&
]
addressed this question in 222 cognitively intact
individuals who underwent baseline lumbar punc-
ture at middle age and cognitive follow-up over a
time period of 11 years. Based on the NIA-AA criteria
[3], the authors classified the individuals according
to their CSF biomarker profiles at baseline into four
hypothetical preclinical Alzheimer’s disease groups:
high Ab42/low total or p-tau (‘stage 0’), low Ab42/
low total or p-tau (‘stage 1’), low Ab42/high total or
p-tau (‘stage 2’) and high Ab42/high total or p-tau
(referred to as suspected non-Alzheimer’s disease
pathology or ‘SNAP’). By using an a priori-defined
cognitive composite score Soldan et al. found sig-
nificantly lower baseline scores and an increased
cognitive decline over time only in the ‘stage 2’
group when compared to the other groups.
In line with these results are findings from a
longitudinal cohort of middle-aged individuals in
which the majority of individuals with cognitive
decline during follow-up exhibited low Ab42 and
high tau/p-tau at baseline and follow-up [16
&&
].
Collectively, these results imply that the pres-
ence of tau pathology in CSF is required for cogni-
tive decline in persons with preclinical Alzheimer’s
disease. An association betweenCSF tau, but not CSF
Ab, and cognitive deficits is further supported by
data from a sample of cognitively intact individuals
revealing a significant relationship between CSF tau
and p-tau and longitudinal impairments on specific
visuospatial episodic memory tasks [24].
In an alternative study, Edmonds et al. [25]
analyzed 570 cognitively normal participants who
were classified either based on the NIA-AA criteria or
separately based on the number of positive CSF
Alzheimer’s disease biomarkers and on operational-
ized criteria defining ‘subtle cognitive decline’ in
preclinical Alzheimer’s disease. Interestingly, base-
line analyses revealed a 2.5 times higher frequency
of abnormal CSF tau levels than abnormal CSF Ab
in this sample; moreover, most of the individuals
who were characterized by only one abnormal CSF
biomarker at baseline and later progressed to MCI
or Alzheimer’s disease dementia turned out to be
tau-positive [25].
In general, the relationship between tau path-
ology and cognitive decline does not exclude the
possibility of tau-independent Ab-related influences
on cognition. In fact, in the cross-sectional study
published by Wang et al. [11
&
], abnormal CSF levels
of Ab42 and tau were not only associated with
spatially distinct patterns of brain atrophy, but also
with independent effects on cognitive performance
in specific neuropsychological tasks.
CANDIDATE CEREBROSPINAL FLUID
BIOMARKERS IN PRECLINICAL
ALZHEIMER’S DISEASE
In the recent years, the involvement of neuro-
inflammatory responses in early Alzheimer’s disease
pathogenesis has received much attention by the
Degenerative and cognitive diseases
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scientific community. Several markers have been
studied with a special focus on YKL-40 (also known
as chitinase 3-like 1 protein), a marker of glial
inflammation. Two recent cross-sectional studies
addressed the relationship between CSF YKL-40
and structural brain changes in cohorts including
individuals with preclinical Alzheimer’s disease.
Alcolea et al. [26] found a strong correlation between
CSF YKL-40 and the neurodegeneration markers
total tau and p-tau in a combined sample of
80 cognitively normal controls and 27MCI patients.
Importantly, CSF YKL-40 levels were strongly corre-
lated with cortical thinning in Alzheimer’s disease-
relevant brain regions associated with tau pathology
and – similar to tau – were modulated by the CSF
Ab42 status suggesting that both tau-driven neuro-
degeneration and YKL-40-related inflammation
affected brain structure in an amyloid-dependent
manner [26]. Although these results imply a contri-
bution of YKL-40-related processes and tau pathol-
ogy to similar structural brain changes, Gispert et al.
[27] recently reported an association of CSF YKL-40
and p-tau with grey matter atrophy in anatomically
distinct brain regions in a cohort of MCI and mild
Alzheimer’s disease individuals as well as normal
controls and individuals with preclinical Alz-
heimer’s disease. In support of these findings, Sut-
phen et al. [16
&&
] observed in their longitudinal
sample a consistent increase in CSF YKL-40 through-
out middle age, which was accelerated by the pres-
ence of the APOE e4 genotype, as were the changes
in both amyloid and neuronal injury markers.
A strong correlation between CSF YKL-40 and age
as well as between YKL-40 and total tau was also
observed in a large cross-sectional study including
266 middle-aged cognitively intact individuals [28].
Interestingly, significantly increased CSF YKL-40
levels were not only detected in individuals with
preclinical Alzheimer’s disease stages 2–3, but also
in participants with SNAP, suggesting that markers
of neuroinflammationmay be of relevance in a wide
range of neurodegenerative conditions including
nonamyloid-related pathologies [28]. In the latter
study, the authors additionally measured CSF sAPPb
levels and b-secretase activity, two candidate bio-
markers involved in amyloid precursor protein
(APP) processing, but found no significant differ-
ences between preclinical Alzheimer’s disease stages
0, 1 and 2–3 [28].
Neuronal loss and synaptic injury are widely
recognized as early correlates of Alzheimer’s dis-
ease-related cognitive decline and clinical disease
progression. Biomarkers of neuronal and synaptic
loss may therefore be particularly useful as staging
biomarkers in preclinical Alzheimer’s disease.
Among the candidate markers reflecting neuronal
injury a special focus has recently been laid on
the neuronal calcium-sensor protein visinin-like
protein 1 (VILIP-1). Analysis of within-person tra-
jectories of CSF biomarkers in middle-aged indivi-
duals included in the study published by Sutphen
et al. [16
&&
] revealed significant increases in CSF
VILIP-1 during mid and late middle age thus resem-
bling the temporal biomarker changes observed for
the neuronal injury markers total tau and p-tau in
this study. Similar to CSF tau and p-tau, baseline CSF
levels of VILIP-1 in the upper tercile were associated
with significantly increased atrophy rates in cogni-
tively normal participants in the longitudinal
study published by Tarawneh et al. [13
&
]. In early
Alzheimer’s disease patients, baseline CSF VILIP-1
levels moreover predicted regional and whole-brain
atrophy at least as well as tau/p-tau [13
&
].
In another cross-sectional and longitudinal
observational study including 207 cognitively intact
control individuals and 95 patients with sympto-
matic Alzheimer’s disease Tarawneh investigated
the diagnostic and prognostic utility of neurogra-
nin, a candidate CSF marker of synaptic injury [29].
Although CSF neurogranin levels differentiated
patients with early Alzheimer’s disease from con-
trols with a diagnostic accuracy comparable to the
core CSF markers, CSF neurogranin also correlated
with cerebral amyloid deposition on amyloid PET in
individuals with preclinical Alzheimer’s disease and
predicted longitudinal cognitive decline in cogni-
tively intact individuals [29]. In combination with
the other CSF biomarkers of Alzheimer’s disease, CSF
neurogranin complemented the predictive ability
for future cognitive decline, thus emphasizing the
utility of its addition to the diagnostic panel in
preclinical Alzheimer’s disease [29].
CONCLUSION
Recent findings support the notion that elevated
CSF tau/p-tau levels and/or Ab/tau interactions are
associated with neurodegeneration in preclinical
Alzheimer’s disease as revealed by Alzheimer’s dis-
ease-characteristic changes on MRI and [18F]FDG
PET, whichwould be in line with the NIA-AA criteria
[3]. However, a low concordance rate between CSF
tau and imagingmarkers of neurodegeneration have
been reported by some authors, and Ab-mediated
tau-independent effects on brain atrophy have been
described, suggesting the need for further research
in this field. Concerning the sequence of temporal
biomarker changes, longitudinal data in cognitively
intact individuals suggest that CSF Ab42 is altered
very early in preclinical Alzheimer’s disease,
even preceding changes on amyloid PET imaging
[16
&&
,18
&
]. The order of temporal changes of CSF Ab
Recent advances in cerebrospinal fluid biomarkers Kulic and Unschuld
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and tau, however, seems to be less clear as suggested
by the NIA-AA criteria given the fact that a strong
temporal coincidence of CSF Ab trajectories tau
trajectories has been observed by some authors. In
the majority of studies, the presence of abnormal
CSF tau/p-tau levels and/or combined Ab and tau
pathology were required for future cognitive deline,
again in agreement with the proposed NIA-AA stag-
ing model [3]. Nevertheless, Ab and tau may also
exert independent effects on cognitive function as
suggested by some authors. The search for novel CSF
biomarkers has led to identification of several can-
didate biomarkers of neuronal and synaptic injury
as well as neuroinflammation, which may comp-
lement CSF-based diagnostics in the different stages
of preclinical Alzheimer’s disease.
FUTURE DIRECTIONS
In addition to structural MRI and PET, a number of
additional MR-based imaging techniques have
recently been applied to study the functional con-
sequences of CSF biomarker abnormalities in indi-
viduals with preclinical Alzheimer’s disease andmay
further contribute to a better understanding of brain
changes in the earliest stages of the disease
[5
&&
,30,31].
To better predict cognitive decline in persons
with preclinical Alzheimer’s disease, the role of
co-pathologies and the contribution of various
lifestyle and risk factors will have to be better under-
stood. In addition to vascular changes and vascular
risk factors [32,33], the role of psychiatric comor-
bidities, such as anxiety and depression, and their
association with preclinical Alzheimer’s disease
biomarkers and cognitive decline will have to be
addressed further in longitudinal studies [34,35].
An under-researched topic in the biomarker
field remains the discovery of novel markers reflect-
ing beneficial clinical outcome and neuroprotec-
tion. As an example, CSF vascular endothelial
growth factor (VEGF) has recently been associated
with beneficial effects on longitudinal atrophy and
cognitive function in the presence of abnormal
Alzheimer’s disease CSF biomarkers [36]. Other pro-
tective factors in preclinical Alzheimer’s disease
include cognitive reserve [23
&&
,37
&
] and engagement
in physical activity [38]. The exact contribution of
these factors to longitudinal cognitive decline and
their association with CSF biomarker changes in
preclinical Alzheimer’s disease will be an important
aim of future research.
APOE e4 represents the major genetic risk factor
for sporadic Alzheimer’s disease. In the study pub-
lished by Sutphen et al. [16
&&
], the APOE e4 genotype
was associated with more pronounced longitudinal
changes of Alzheimer’s disease-related biomarker
trajectories in cognitively normal individuals
during middle age in whom it modified CSF Ab42
levels in allele dose-dependent manner. Whether
Alzheimer’s disease biomarkers, including markers
of cerebral amyloid plaque deposition, and APOE e4
act independently or interact with each other to
influence longitudinal cognitive decline is still a
matter of debate. Although Soldan et al. [23
&&
]
reported an overrepresentation of APOE e4 carriers
in individuals with stage 2 preclinical Alzheimer’s
disease, the APOE e4 genotype did not significantly
modify the rate of cognitive decline in this study.
These results are in contrast to the findings obtained
from several recent preclinical Alzheimer’s disease
studies suggesting an interaction between Ab pos-
itivity, as determined by amyloid PET imaging, and
APOE e4 genotype on the progression of future
cognitive symptoms [39–43]. Taken together,
additional longitudinal studies with genetic and
CSF biomarker data from larger sample sizes will
be necessary to delineate the role of APOE e4 and
its interaction with core CSF Alzheimer’s disease
biomarkers in longitudinal cognitive decline.
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